Anjeso (Meloxicam Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 27, 2020 Category: Drugs & Pharmacology Source Type: news
Anjeso (Meloxicam Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 26, 2020 Category: Drugs & Pharmacology Source Type: news
FDA OKs First Once-Daily IV COX-2 Preferential NSAID for Pain FDA OKs First Once-Daily IV COX-2 Preferential NSAID for Pain
The FDA approved meloxicam injection (Anjeso, Baudax Bio) for the treatment of moderate to severe pain, either by itself or with other NSAID analgesics.FDA Approvals (Source: Medscape Med Students Headlines)
Source: Medscape Med Students Headlines - February 21, 2020 Category: Universities & Medical Training Tags: Neurology & Neurosurgery News Alert Source Type: news
FDA Approves Anjeso (meloxicam injection) for the Management of Moderate to Severe Pain
MALVERN, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 20, 2020 Category: Drugs & Pharmacology Source Type: news
Malvern pharma firm wins FDA appeal, moves forward with spinoff plans
Recro Pharma has won an appeal it filed with the Food and Drug Administration, moving a step closer to launching its first internally developed product.
The Malvern-based specialty pharmaceutical company — which also said it is moving ahead with plans to spinoff its acute-care business segment —appealed the FDA’s rejection of its new drug application for intravenous meloxicam.
Recro is seeking to market IV meloxicam as a non-opioid treatmen t to manage moderate-to-severe pain for patients… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 31, 2019 Category: Biotechnology Authors: John George Source Type: news
Malvern pharma firm wins FDA appeal, moves forward with spinoff plans
Recro Pharma has won an appeal it filed with the Food and Drug Administration, moving a step closer to launching its first internally developed product.
The Malvern-based specialty pharmaceutical company — which also said it is moving ahead with plans to spinoff its acute-care business segment —appealed the FDA’s rejection of its new drug application for intravenous meloxicam.
Recro is seeking to market IV meloxicam as a non-opioid treatmen t to manage moderate-to-severe pain for patients… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 31, 2019 Category: Pharmaceuticals Authors: John George Source Type: news
Zyla Life Sciences Announces Management Changes
WAYNE, Pa., Oct. 23, 2019 -- (Healthcare Sales & Marketing Network) -- Zyla Life Sciences (OTCQX: ZCOR) ("Zyla"), a commercial-stage life sciences company, today announced that Robert Radie, has resigned as president, chief executive officer and... Biopharmaceuticals, Personnel Zyla Life Sciences, SPRIX, ketorolac tromethamine, ZORVOLEX, VIVLODEX, meloxicam (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 23, 2019 Category: Pharmaceuticals Source Type: news
meloxicam (Mobic) Side Effects
Title: meloxicam (Mobic) Side EffectsCategory: MedicationsCreated: 11/8/2000 12:00:00 AMLast Editorial Review: 6/27/2019 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - June 27, 2019 Category: Rheumatology Source Type: news
Zyla Life Sciences Appoints Dr. H. Jeffrey Wilkins as Chief Medical Officer
WAYNE, Pa., June 12, 2019 -- (Healthcare Sales & Marketing Network) -- Zyla Life Sciences (OTCQX:ZCOR) ("Zyla"), a growing commercial-stage life sciences company, announced the appointment of H. Jeffrey Wilkins, M.D. as senior vice president and... Biopharmaceuticals, Personnel Zyla Life Sciences, SPRIX, ketorolac tromethamine, ZORVOLEX, VIVLODEX, meloxicam (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 12, 2019 Category: Pharmaceuticals Source Type: news
Celebrating 20 years of Metacam for cattle
Boehringer Ingelheim celebrates 20 years of Metacam ® for cattle2019 marks the anniversary of Metacam ® (meloxicam) for cattleOriginally licenced for dogs, Metacam ®can be used in other species to treat inflammatory and painful conditionsBoehringer Ingelheim celebrates this 20-year milestone since pioneering meloxicam for use in both humans and animals (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 11, 2019 Category: Research Source Type: news
Recro Pharma eliminates 50 jobs following FDA setback
Recro Pharma Inc. is eliminating about 50 positions in its acute care segment, and seeking a partner to commercialize its lead new drug candidate.
Both moves come about two weeks after the Food and Drug Administration for a second time turned down the Malvern, Pa, pharmaceutical company's new drug application for intravenous meloxicam.
Recro is seeking to market IV meloxicam, a non-opioid, as a treatment to manage moderate-to-severe pain. The company, which also operates a revenue-generating contract… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 4, 2019 Category: American Health Authors: John George Source Type: news
Why Recro Pharma's stock price plunged more than 34% today
Recro Pharma's stock price plummeted more than 34 percent to $6.41 per share Monday, the first day of trading after the Food and Drug Administration's rejection of the Malvern pharmaceutical company's new drug application for a non-opioid pain medicine.
On Friday, the FDA voted against granting marketing approval to Recro for its intravenous meloxicam drug to managed moderate-to-severe pain.
The FDA initially rejected the company's new drug application for the medicine last year. Recro (NASDAQ:… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 25, 2019 Category: American Health Authors: John George Source Type: news
Why Recro Pharma's stock price plunged more than 34% today
Recro Pharma's stock price plummeted more than 34 percent to $6.41 per share Monday, the first day of trading after the Food and Drug Administration's rejection of the Malvern pharmaceutical company's new drug application for a non-opioid pain medicine.
On Friday, the FDA voted against granting marketing approval to Recro for its intravenous meloxicam drug to managed moderate-to-severe pain.
The FDA initially rejected the company's new drug application for the medicine last year. Recro (NASDAQ:… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 25, 2019 Category: Biotechnology Authors: John George Source Type: news
FDA rejects Malvern pharma firm's non-opioid pain killer for a second time
The Food and Drug Administration once again failed to approve Recro Pharma's new drug application for its experimental non-opioid pain medication intravenous meloxicam.
The federal agency, in its complete response letter (CRL) to the Malvern, Pa.-based pharmaceutical company, said the delayed onset of IV meloxicam fails to meet the prescriber expectations for intravenous drugs. The letter, according to Recro, also cited regulatory concerns about the role of IV meloxicam as a monotherapy in acute… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 22, 2019 Category: American Health Authors: John George Source Type: news
FDA rejects Malvern pharma firm's non-opioid pain killer for a second time
The Food and Drug Administration once again failed to approve Recro Pharma's new drug application for its experimental non-opioid pain medication intravenous meloxicam.
The federal agency, in its complete response letter (CRL) to the Malvern, Pa.-based pharmaceutical company, said the delayed onset of IV meloxicam fails to meet the prescriber expectations for intravenous drugs. The letter, according to Recro, also cited regulatory concerns about the role of IV meloxicam as a monotherapy in acute… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 22, 2019 Category: Biotechnology Authors: John George Source Type: news
